[1] D’Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol, 2016, vol. 44, № 1, pp. 217-231.
[2] Al Hamoudi W., Lee S.S. Cirrhotic cardiomyopathy. Ann Hepatol, 2005, vol. 5, № 3, pp. 132-139.
[3] Gaskari S.A., Honar H., Lee S.S. Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol, 2006, vol. 3, № 6, pp. 329-337.
[4] Liu H., Lee S.S. What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology, 2015, vol. 42, № 5, pp. 1203-1205.
[5] Myers R.P., Lee S.S. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2010, vol. 6, Suppl. 1, pp. 44-52.
[6] Therapondos G., Flapan A.D., Plevris J.N., Hayes P.C. Cardiac morbidity and m ortality related to orthotopic liver transplantation. Liver Transpl, 2004, vol. 10, № 12, pp. 1441-1453.
[7] M oller S., Henriksen J.H. Cardiovascular dysfunction incirrhosis: pathophysiological evidence of a cirrhotic cardiomyopathy. S c a n d J Gastroenterol, 2001, vol. 36, pp. 785-794.
[8] Kim M.Y., Baik S.K. Cirrhotic cardiomyopathy. Korean J Hepatol, 2007, vol. 13, № 1, pp. P. 20-26.
[9] Cazzaniga M., Salerno F., Pagnozzi G., Dionigi E., Visentin S., Cirello I., Meregaglia D., Nicolini A. Diastolic dysfunction is associated with poor survival in patients with cirrho sis w ith tra nsjug ula r intrahepatic portosystemic shunt. Gut, 2007, vol. 56, № 6, pp. 869-875.
[10] Moller S., Henriksen J.H. Cardiovascular complications of cirrhosis. Gut 2008, vol. 57, № 2, pp. 268-278.
[11] Liu H., Gaskari S.A., Lee S.S. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol, 2006, vol. 12, № 6, pp. 837-842.
[12] Lee S.S. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology, 2003, vol. 38, № 5, pp. 1089-1091.
[13] Ruiz-del-Arbol L , Monescillo A., Arocena C., Valer P., Gines P., Moreira V., Milicua J.M., Jimenez W., Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005, vol. 42, pp. 439-447.
[14] Pozzi M., Grassi G., Ratti L., Favini G., Dell’Oro R., Redaelli E., Calchera I., Boari G., Mancia G. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol, 2005, vol. 100, № 5, pp. 1110-1116.
[15] Pacher P., Batkai S., Kunos G. Cirrhotic cardiomyopathy: an endocannabi- noid connection? Br J Pharmacol, 2005, vol. 146, № 3, pp. 313-314.
[16] Rabie R., Cazzaniga M., Salerno F., Wong F. The effect of cirrhotic cardiomyopathy on the pos-TIPS outcome of patients treated for complications of portal hypertension. Hepatology, 2006, vol. 44, Suppl. 1, pp. 444A.
[17] Trevisani F., Merli M., Savelli F., Valeriano V., Zambruni A., Riggio O., Caraceni P., Domenicali M., Bernardi M. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. J Hepatol, 2003, vol. 38, № 4, pp. 461-467.
[18] Ford W.R., Honan S.A., White R., Hiley C.R. Evidence of a novel site mediating anandamide induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol, 2002, vol. 135, № 5, pp. 1191-1198.
[19] Torregrosa M., Aguade S., Dos L , Segura R., Gonzalez A., Evangelista A., Castell J., MargaritC., Esteban R., Guardia J., GenescaJ., Cardiac alterations reversibility after liver transplantation. J Hepatol, 2005, vol. 42, № 1, pp. 68-74.
[20] Acosta F., De La Morena G., Villegas M., Sansano T., Reche M., Beltran R., Roques V., Contreras R.F., Robles R., Bueno F.S., Ramirez P., Parrilla P. Evaluation of cardiac function before and after liver transplantation. Transplant Proc, 1999, vol. 31, № 6, pp. 2369-2370.
[21] Al-Hamoudi W., Alqahtani S., Tandon P., Ma M., Lee S.S. Hemodynamics in the immediate post-transplantation period in alcoholic and viral cirrhosis. World J Gastroenterol, 2010, vol. 16, № 5, pp. 608-612.
[22] Carey E.J., Douglas D.D. Effects of orthotopic liver transplantation in patients with end-stage liver disease. Dig Dis Sci, 2005, vol. 50, № 2, pp. 320-323.
[23] Ruiz-del-Arbol L , Monescillo A., Arocena C., Valer P., Gines P., Moreira V., Milicua J.M., Jimenez W., Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology, 2005, vol. 42, № 2, pp. 439-447.
[24] Pateron D., Beyne P., Laperche T., Logeard D., Lefilliatre P., Sogni P., Moreau R., Langlet P., Elman A., Bernuau J., Valla D., Erlinger S., Lebrec D. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology, 1999, vol. 29, № 3, pp. 640-643.
[25] Pozzi M., Carugo S., Boari G., Pecci V., de Ceglia S., Maggiolini S., Bolla G.B., Roffi L., Failla M., Grassi G., Giannattasio C., Mancia G. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology, 1997, vol. 26, № 5, pp. 1131-1137.
[26] Nasraway S.A., Klein R.D., Spanier T.B. et al. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation: evidence for early postoperative myocardial depression. Chest 1995, vol. 107, № 1, pp. 218-224.
[27] Ocel J.J., Edwards W.D., Tazelaar H.D., Petrovic L.M., Edwards B.S., Kamath P.S. Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation. Mayo Clin Proc, 2004, vol. 79, № 4, pp. 492-450.
[28] Silver M.A., Maisel A., Yancy C.W., McCullough P.A., Burnett J.C. Jr, Francis G.S., Mehra M.R., Peacock W.F. 4th, Fonarow G., Gibler W.B., Morrow D.A., Hollander J. BNP Consensus Panel. BNP Consensus Panel 2014: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail, 2004, vol. 10, Suppl. 3, pp. 1-30.
[29] Grigorenko E.A., Mitkovskaya N.P., Rummo O.O., Kalachik O.V. Strukturnofunkzional’nye izmeneniya kardiovaskulyarnoy sistemy, lipidnye i gemostaziologicheskie narusheniya posle transplantazii pecheni i pochek [Structural and functional changes of cardiovascular system, lipid and emostaziological violations after kidney and liver transplantation]. Medizinskiy zhurnat 2013, № 1, pp. 67-70.